Table 1.
Characteristics of the Chronic Renal Insufficiency Cohort Study participants without heart failure by quartile of left ventricular mass index
| Characteristic | LVMI Quartiles (N, g/m2.7) | |||||
|---|---|---|---|---|---|---|
| 641 (<41.3) | 643 (41.3 to <48.5) | 642 (48.5 to <57.5) | 641 (≥57.5) | P Value | Linear Trend P Value | |
| Age, yr | 58.0 [46.0, 64.0] | 60.0 [52.0, 66.0] | 61.0 [54.0, 67.0] | 62.0 [56.0, 67.0] | <0.001 | <0.001 |
| Sex | ||||||
| Men | 327 (51.0%) | 345 (53.7%) | 365 (57%) | 341 (53.2) | 0.21 | 0.31 |
| Women | 314 (49%) | 298 (46.4%) | 277 (43.2%) | 300 (46.8%) | ||
| Race | ||||||
| Non-Hispanic white | 393 (61.3%) | 305 (47.4%) | 255 (39.7%) | 164 (25.6%) | <0.001 | <0.001 |
| Non-Hispanic black | 188 (29.3%) | 238 (37.%) | 267 (41.6%) | 314 (49%) | ||
| Hispanic | 35 (5.5%) | 70 (10.9%) | 95 (14.8%) | 140 (21.8%) | ||
| Other | 25 (3.9%) | 30 (4.7%) | 25 (3.9%) | 23 (3.6%) | ||
| Diabetes | 186 (29%) | 262 (40.8%) | 327 (50.9%) | 410 (64%) | <0.001 | <0.001 |
| History of hypertension | 480 (74.9%) | 548 (85.2%) | 591 (92.1%) | 624 (97.4%) | <0.001 | <0.001 |
| History of cardiovascular diseasea | 101 (15.8%) | 137 (21.3%) | 190 (29.6%) | 254 (39.6%) | <0.001 | <0.001 |
| Tobacco use | 74 (11.5%) | 69 (10.7%) | 76 (11.8%) | 81 (12.6%) | 0.76 | 0.27 |
| Alcohol use | 457 (71.3%) | 396 (61.6%) | 383 (59.7%) | 310 (48.4%) | <0.001 | <0.001 |
| Systolic BP, mmHg | 117.2 (16.4) | 124.3 (19.1) | 128.8 (20.5) | 137.5 (24.6) | <0.001 | <0.001 |
| Diastolic BP, mmHg | 69.8 (10.9) | 70.2 (11.8) | 70.7 (12.9) | 71.8 (14.1) | 0.03 | <0.001 |
| Body mass index, kg/m2 | 27.3 (5.1) | 30.1 (6.1) | 32.6 (6.4) | 35.6 (7.9) | <0.001 | <0.001 |
| Angiotensin–converting enzyme inhibitor or ARB | 414 (64.6%) | 431 (67%) | 460 (71.7%) | 455 (71.2%) | 0.02 | 0.01 |
| Diuretics | 253 (39.5%) | 317 (49.3%) | 387 (60.3%) | 458 (71.7%) | <0.001 | <0.001 |
| β-Blockers | 196 (30.6%) | 266 (41.4%) | 314 (48.9%) | 398 (62.3%) | <0.001 | <0.001 |
| Aldosterone antagonists | 16 (2.50%) | 12 (1.9%) | 23 (3.6%) | 23 (3.6%) | 0.17 | 0.08 |
| Aspirin | 220 (34%) | 267 (42%) | 297 (46%) | 315 (49%) | <0.001 | <0.001 |
| Statin | 322 (50%) | 355 (55%) | 374 (58%) | 422 (66%) | <0.001 | 0.08 |
| Ejection fraction, % | 55.9 (6.1) | 55.8 (6.8) | 55.3 (7.0) | 53.6 (9.0) | <0.001 | <0.001 |
| Ln(24-h proteinuria) | 0.1 [0.1, 0.3] | 0.1 [0.1, 0.4] | 0.1 [0.1, 0.6] | 0.4 [0.1, 1.1] | <0.001 | <0.001 |
| eGFR, ml/min per 1.73 m2 | 49.9 (16.9) | 46.6 (17.1) | 41.8 (16.5) | 37.3 (14.5) | <0.001 | <0.001 |
| LDL, mg/dl | 103.9 (34.3) | 104.0 (35.4) | 101.0 (34.3) | 97.2 (35.1) | 0.001 | <0.001 |
| HDL, mg/dl | 53.2 (17.9) | 50.0 (15.1) | 47.3 (15.6) | 45.1 (13.0) | <0.001 | <0.001 |
| Calcium, mg/dl | 9.4 (0.5) | 9.4 (0.5) | 9.3 (0.5) | 9.2 (0.6) | <0.001 | <0.001 |
| Phosphate, mg/dl | 3.6 (0.6) | 3.7 (0.6) | 3.7 (0.6) | 3.9 (0.7) | <0.001 | <0.001 |
| Hemoglobin, mg/dl | 13.5 (1.6) | 13.0 (1.7) | 12.8 (1.7) | 12.1 (1.8) | <0.001 | <0.001 |
| PTH, pg/ml | 48.0 [33.7, 70.3] | 54.1 [36.0, 85.0] | 58.0 [39.5, 97.0] | 74.7 [47.9, 120.0] | <0.001 | <0.001 |
| FGF23, RU/ml | 107.0 [75.6, 164.6] | 124.0 [84.7, 194.3] | 134.5 [92.7, 208.3] | 167.7 [109.9, 280.0] | <0.001 | <0.001 |
| BNP, pg/ml | 23.6 [7.6, 51.5] | 30.5 [12.8, 65.3] | 38.1 [16.4, 85.9] | 59.5 [22.4, 125.2] | <0.001 | <0.001 |
| Troponin T, pg/ml | 6.3 [1.5, 11.5] | 8.6 [4.4, 16.1] | 12.2 [6.1, 21.1] | 17.5 [9.7, 32.6] | <0.001 | <0.001 |
Entries in first four columns are number (percent) or mean [range]. P value by chi-squared test for categorical variables or ANOVA for continuous variables. LVMI, left ventricular mass index; ARB, angiotensin receptor blocker; PTH, parathyroid hormone; FGF23, fibroblast growth factor-23; BNP, B–type natriuretic peptide.
a
Coronary artery disease, peripheral vascular disease, or stroke.